JP2020529847A5 - - Google Patents

Download PDF

Info

Publication number
JP2020529847A5
JP2020529847A5 JP2020505464A JP2020505464A JP2020529847A5 JP 2020529847 A5 JP2020529847 A5 JP 2020529847A5 JP 2020505464 A JP2020505464 A JP 2020505464A JP 2020505464 A JP2020505464 A JP 2020505464A JP 2020529847 A5 JP2020529847 A5 JP 2020529847A5
Authority
JP
Japan
Prior art keywords
cancer
immune cells
types
cells
lymphocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020505464A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020529847A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/044740 external-priority patent/WO2019028098A1/en
Publication of JP2020529847A publication Critical patent/JP2020529847A/ja
Publication of JP2020529847A5 publication Critical patent/JP2020529847A5/ja
Pending legal-status Critical Current

Links

JP2020505464A 2017-08-03 2018-08-01 がんの処置のための方法および組成物 Pending JP2020529847A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762540901P 2017-08-03 2017-08-03
US62/540,901 2017-08-03
PCT/US2018/044740 WO2019028098A1 (en) 2017-08-03 2018-08-01 METHODS AND COMPOSITIONS FOR TREATING CANCER

Publications (2)

Publication Number Publication Date
JP2020529847A JP2020529847A (ja) 2020-10-15
JP2020529847A5 true JP2020529847A5 (cg-RX-API-DMAC7.html) 2021-09-09

Family

ID=65234162

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020505464A Pending JP2020529847A (ja) 2017-08-03 2018-08-01 がんの処置のための方法および組成物

Country Status (10)

Country Link
US (1) US20200155600A1 (cg-RX-API-DMAC7.html)
EP (1) EP3661953A4 (cg-RX-API-DMAC7.html)
JP (1) JP2020529847A (cg-RX-API-DMAC7.html)
KR (1) KR20200036874A (cg-RX-API-DMAC7.html)
CN (1) CN111094328A (cg-RX-API-DMAC7.html)
AU (1) AU2018308982A1 (cg-RX-API-DMAC7.html)
CA (1) CA3071448A1 (cg-RX-API-DMAC7.html)
IL (1) IL272147A (cg-RX-API-DMAC7.html)
SG (1) SG11202000724XA (cg-RX-API-DMAC7.html)
WO (1) WO2019028098A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020272664A1 (en) * 2019-04-08 2021-11-04 Taiga Biotechnologies, Inc. Compositions and methods for the cry opreservation of immune cells
CA3137031A1 (en) * 2019-05-14 2020-11-19 Yosef Refaeli Compositions and methods for treating t cell exhaustion

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358739B1 (en) * 1999-04-12 2002-03-19 Modex Therapeutiques, S.A. Transiently immortalized cells
AU2872202A (en) * 2000-11-01 2002-05-15 Us Gov Health & Human Serv Expression vectors able to elicit improved immune response and methods of using same
AU2003216288B2 (en) * 2002-02-13 2009-09-24 Duke University Modulation of immune response by non-peptide binding stress response polypeptides
AU2004316996A1 (en) * 2003-06-20 2005-09-15 The Regents Of The University Of California Polypeptide transduction and fusogenic peptides
IL286053B2 (en) * 2005-10-18 2023-03-01 Nat Jewish Health A process for making red blood cells using immortal hematopoietic stem cells and erythropoietin
ES2879225T3 (es) * 2008-08-28 2021-11-22 Taiga Biotechnologies Inc Moduladores de MYC, métodos de uso de los mismos, y métodos para identificar agentes que modulan MYC
ES2856179T3 (es) * 2012-07-20 2021-09-27 Taiga Biotechnologies Inc Reconstitución y autorreconstitución potenciadas del compartimento hematopoyético
US9365825B2 (en) * 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
CA2909432C (en) * 2013-04-18 2025-11-18 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy
US10149898B2 (en) * 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
WO2019027465A1 (en) * 2017-08-03 2019-02-07 Taiga Biotechnologies, Inc. PHARMACEUTICAL METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA

Similar Documents

Publication Publication Date Title
Sun et al. Eradication of hepatocellular carcinoma by NKG2D-based CAR-T cells
ES3037919T3 (en) Mage a4 t cell receptors
JP2021058197A5 (cg-RX-API-DMAC7.html)
US11970545B2 (en) T cell-antigen coupler with Y182T mutation and methods of uses thereof
CN111629734A (zh) 用于共刺激的新型平台、新型car设计以及过继性细胞疗法的其他增强
TW201619377A (zh) Car表現載體及car表現t細胞
JP2019516663A5 (cg-RX-API-DMAC7.html)
Franks et al. New anticancer immunotherapies
JP2020516681A5 (cg-RX-API-DMAC7.html)
WO2021048724A1 (en) Combined expression of a chimeric cd3 fusion protein and an anti-cd3-based bispecific t cell activating element
IL301995A (en) Cells comprising t cell-antigen couplers and uses thereof
JP2020529847A5 (cg-RX-API-DMAC7.html)
JPWO2020154617A5 (cg-RX-API-DMAC7.html)
Long et al. HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice
CN115023237A (zh) 癌症或肿瘤的治疗方法
Tang et al. Bispecific antibodies progression in malignant melanoma
WO2022033483A1 (zh) 多功能的免疫效应细胞及其应用
JPWO2019157524A5 (cg-RX-API-DMAC7.html)
US12479903B2 (en) CD5 specific T cell receptor cell or gene therapy
CA3195627A1 (en) Il-2/il-15r.beta..gamma. agonist for treating squamous cell carcinoma
CN108025044B (zh) 免疫原性降钙素原前体肽
US20240226210A9 (en) Oncolytic virus combined with car t cells for anti-tumor therapy
US20250043021A1 (en) Gpc3 t cell-antigen couplers and uses thereof
US20230053849A1 (en) Anti trbc1 antigen binding domains
KR20240002205A (ko) 면역관문 제어 인자를 발현하는 면역세포 및 이의 용도